Advanced Non Small Cell Lung Cancer, HER2 Mutation

SEP 10, 2026 · PHASE 3 TRIAL

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

ClinicalTrials.gov

Phase 3 trial registration with no results posted; describes planned enrollment and design only, supporting no current evidence of efficacy or safety.